New cancer-causing toxin found in recalled blood pressure pills
(Reuters) – U.S. health regulators said on Friday a third cancer-causing toxin was found in some blood pressure pills recalled by India’s Hetero Labs Ltd a day earlier, adding to…
Parkinson’s drug trial offers glimmer of hope for brain cells
LONDON, Feb 27 (Reuters) – An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial…
Savencia unit recalls baby milk in France after salmonella alert
PARIS (Reuters) – Sodilac, a unit of French dairy group Savencia, said it was recalling infant formula sold in pharmacies in France and produced at a Spanish factory due to…
China orders halt to gene-editing after outcry over babies
SHANGHAI (Reuters) – The Chinese government on Thursday ordered a temporary halt to research activities for people involved in the editing of human genes, after a Chinese scientist said he…
Congo Republic confirms yellow fever near Angolan enclave
BRAZZAVILLE (Reuters) – Congo Republic has confirmed a case of yellow fever near the border with an Angolan enclave, the health ministry said on Tuesday, and has warned of “an…
West Nile virus cases in Greece jump in 2018
ATHENS (Reuters) – Eleven people have died and 107 infected by the mosquito-borne West Nile virus in Greece so far this summer, authorities said, the highest number of reported cases…
Long-acting injection a shot in the arm for GSK’s HIV business
LONDON (Reuters) – A long-acting injection developed by GlaxoSmithKline (GSK.L) and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects…
Congo declares new Ebola outbreak in eastern province
GOMA, Democratic Republic of Congo (Reuters) – Four people have tested positive for Ebola in eastern Democratic Republic of Congo just days after another outbreak that killed 33 people in…
Mersana’s cancer drug trial put on hold by FDA; shares halted
(Reuters) – Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after…
CRISPR gene editing can cause risky collateral DNA damage: study
LONDON (Reuters) – Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in…